What are the indications, recommended dosing, administration technique, and monitoring for Praluent (evolocumab) 75 mg/mL subcutaneous auto‑injector?

Praluent (Alirocumab) 75 mg/mL Subcutaneous Auto-Injector

Start Praluent at 75 mg subcutaneously every 2 weeks for adults with established cardiovascular disease or primary hyperlipidemia (including heterozygous familial hypercholesterolemia) as adjunctive therapy to maximally tolerated statins, escalating to 150 mg every 2 weeks if LDL-C reduction is inadequate after 4 weeks. 1

FDA-Approved Indications

Praluent is indicated for 1:

• Cardiovascular risk reduction: Reduce risk of myocardial infarction, stroke, and unstable angina requiring hospitalization in adults with established cardiovascular disease
• Primary hyperlipidemia: Lower LDL-C as adjunct to diet, alone or with other lipid-lowering therapies, in adults with primary hyperlipidemia including heterozygous familial hypercholesterolemia (HeFH)
• Homozygous familial hypercholesterolemia (HoFH): Lower LDL-C as adjunct to other therapies in adults
• Pediatric HeFH: Lower LDL-C in patients aged 8 years and older with HeFH

Recommended Dosing

Adults with Established CVD or Primary Hyperlipidemia 1

• Starting dose: 75 mg subcutaneously every 2 weeks OR 300 mg every 4 weeks
• Dose escalation: If LDL-C response inadequate, increase to 150 mg every 2 weeks
• Assessment timing: Measure LDL-lowering effect as early as 4 weeks after initiation

Critical caveat: For patients on the 300 mg every 4 weeks regimen, measure LDL-C just prior to the next scheduled dose, as LDL-C can fluctuate between doses in some patients 1.

Adults with HeFH on Apheresis or HoFH 1

• Fixed dose: 150 mg every 2 weeks
• Apheresis timing: Can be administered without regard to timing of LDL apheresis

Pediatric Patients (≥8 years) with HeFH 1

• Body weight <50 kg: 150 mg every 4 weeks; escalate to 75 mg every 2 weeks if inadequate response
• Body weight ≥50 kg: 300 mg every 4 weeks; escalate to 150 mg every 2 weeks if inadequate response

Administration Technique

Preparation 1

1. Warm to room temperature: Allow 30-40 minutes if refrigerated
2. Visual inspection: Solution should be clear, colorless to pale yellow
   • Do not use if cloudy, discolored, or contains particles

Injection Sites 1

• Approved locations: Thigh, abdomen, or upper arm
• Avoid areas: Tender, bruised, red, or indurated skin
• Rotate sites: Use different injection site for each administration

For 300 mg Dose 1

• Administer two consecutive 150 mg injections at two different injection sites

Supervision Requirements 1

• Ages 8-11 years: Must be given by caregiver
• Ages 12-17 years: Recommended to be given by or under supervision of an adult

Missed Dose Management 1

If Missed Within 7 Days

• Administer immediately and resume original schedule

If Missed >7 Days

• Every 2-week dosing: Wait until next scheduled dose
• Every 4-week dosing: Administer immediately and start new schedule based on this date

Expected Efficacy

Alirocumab reduces LDL-C by 45-58% when added to maximally tolerated statin therapy 2:

• 75 mg every 2 weeks: 45% additional LDL-C reduction
• 150 mg every 2 weeks: 58% additional LDL-C reduction
• Also reduces Lp(a) by 25-30% 3

Monitoring

• Initial assessment: Check LDL-C at 4 weeks after initiation or dose adjustment 1
• Ongoing monitoring: Assess LDL-C when clinically appropriate
• Hypersensitivity surveillance: Monitor for signs/symptoms of allergic reactions throughout treatment 1

Safety Considerations

Contraindications 1

Absolute contraindication: History of serious hypersensitivity reaction to alirocumab or any excipient

Warnings 2, 1

• Hypersensitivity reactions: Hypersensitivity vasculitis, angioedema, and reactions requiring hospitalization have occurred
  • If serious reaction occurs: Discontinue immediately, treat per standard of care, monitor until resolution

Common Adverse Effects 2

• Primary hyperlipidemia patients: Nasopharyngitis, injection site reactions, influenza
• ASCVD patients: Noncardiac chest pain, nasopharyngitis, myalgia
• No evidence of increased cognitive adverse effects (ODYSSEY Outcomes, CANTAB trials)

Clinical Context from Guidelines

The 2022 ACC Expert Consensus 2 positions PCSK9 inhibitors like alirocumab for patients who:

• Remain above LDL-C goal despite maximally tolerated statin therapy
• Have confirmed adherence to current regimen
• Have already been optimized on statin plus ezetimibe when appropriate

The ODYSSEY Outcomes trial demonstrated that alirocumab reduced the composite endpoint of CHD death, MI, ischemic stroke, or hospitalization for unstable angina in 18,600 post-ACS patients on evidence-based statin therapy 2.

Practical Prescribing Considerations 2

• Provides robust LDL-C reduction
• Subcutaneous administration at home (patient convenience)
• May require prior authorization (cost consideration)
• Alternative to injectable evolocumab with similar mechanism of action